Bacteria: Gram-negative

Haemophilus influenzae

including H. influenzae type b (Hib)

General medical information for education only, not medical advice. Treatment considerations summarize published guidance at drug-class level; therapy is chosen by the treating clinician using susceptibility results, local resistance patterns and current guidelines.

Overview

A small Gram-negative coccobacillus of the upper airway. Type b was a major cause of childhood meningitis before vaccination; non-typeable strains cause most current respiratory infection.

Infections

Otitis media, sinusitis, bronchitis and exacerbations of chronic lung disease, pneumonia; invasive disease (meningitis, epiglottitis, bacteremia), especially type b.

Signs and symptoms

Cough, sputum, fever, ear or sinus pain; neck stiffness, headache and fever in meningitis.

Antibiotic and antimicrobial resistance

Beta-lactamase production causes ampicillin resistance in a substantial share of isolates.

Treatment considerations

Amoxicillin-clavulanate, second- or third-generation cephalosporins, or other agents guided by susceptibility; ceftriaxone for invasive disease.

Infection control and public health

Invasive disease is nationally notifiable; close contacts of Hib cases may need prophylaxis.

Small Haemophilus influenzae colonies on a red agar plate
Haemophilus influenzae colonies on agar. CDC Public Health Image Library; public domain. Image source
Gram-negative coccobacilli, schematic
Gram-negative coccobacilli. Schematic, not to scale; InnovexLab.

Sources

  1. CDC. Haemophilus influenzae disease.
  2. ATS / IDSA. Community-Acquired Pneumonia in Adults guideline.

Sources accessed November 2026. Links open external sites that InnovexLab does not control.

Medical disclaimer

This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.

Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.

Sources, image credits and editorial policy

Discuss a testing program with InnovexLab

Review the panel that fits your patients, its specimen requirements, and how results and billing work.